{"id":1461,"date":"2024-01-05T07:56:09","date_gmt":"2024-01-05T07:56:09","guid":{"rendered":"https:\/\/aqqute.com\/blog\/?p=1461"},"modified":"2024-01-05T07:56:09","modified_gmt":"2024-01-05T07:56:09","slug":"cancer-can-be-eliminated-with-this-technology","status":"publish","type":"post","link":"https:\/\/aqqute.com\/blog\/2024\/01\/05\/cancer-can-be-eliminated-with-this-technology\/","title":{"rendered":"Cancer can be eliminated with this technology"},"content":{"rendered":"

Pancreas: nanoparticles for optimized cancer therapy<\/span><\/p>\n

Researchers from G\u00f6ttingen and Karlsruhe have developed a new treatment approach for pancreatic cancer.<\/span><\/p>\n

The innovative method promises to be able to treat the disease in a more targeted way and with fewer side effects in the future. The therapy is now to be optimized for clinical application as quickly as possible.<\/span><\/p>\n

Pancreatic cancer is one of the deadliest types of cancer in humans. It is the fourth leading cause of cancer-related deaths in the Western world. The early stages of the disease often progress without symptoms, so diagnosis is usually very late. Another problem: Advanced tumors \u2013 and their metastases \u2013 can no longer be completely removed. Chemotherapies, in turn, attack not only the tumor cells but also healthy cells throughout the body. Innovative nanoparticles could be a new approach to treat cancer more precisely.<\/span><\/p>\n

An interdisciplinary research team from the Max Planck Institute (MPI) for Multidisciplinary Sciences, the University Medical Center G\u00f6ttingen (UMG), and the Karlsruhe Institute of Technology (KIT) have developed a method that promises to treat pancreatic carcinomas with more accuracy and with fewer side effects than current cancer therapies. Using so-called nanoparticles, they transported the active substance Gemcitabine in large quantities directly into the tumor.<\/span><\/p>\n

\u201cTargeting the drug in high concentrations into the tumor cells with the help of the nanoparticles increases the efficacy and spares healthy cells. This can reduce the severe side effects that occur with Gemcitabine,\u201d explains Myrto Ischyropoulou, lead author of the study recently published in the journal Advanced Materials. \u201cCurrently, patients are given the free drug. This is distributed throughout the body and can lead to toxic effects in all parts of the body. The nanoparticles, on the other hand, release the drug mainly in the tumor.\u201d Joanna Napp, scientist at the UMG, adds: \u201cUsing imaging methods, we have already been able to demonstrate in mouse models that the nanoparticles accumulate in the tumors.\u201d<\/span><\/p>\n

The administration of nanoparticles also allows resistance mechanisms in the tumor to be circumvented. \u201cFree Gemcitabine is often no longer taken up by the tumor very early on and is thus largely ineffective there. However, it still leads to considerable side effects, for example in the liver and kidneys,\u201d explains Claus Feldmann from KIT. \u201cBy using a different uptake mechanism in tumor cells, our nanoparticles could be a very effective new therapeutic approach here.\u201d<\/span><\/p>\n

The research success is an excellent example of successful interdisciplinary cooperation, says Frauke Alves, group leader at the MPI and the UMG. \u201cFrom the idea to the development of the new nanoparticles to preclinical testing, chemists, biologists, pharmacists, and physicians have worked hand in hand.\u201d With a spin-off, the scientists are now working to bring their new nanoparticles out of the test phase and into clinical use as quickly as possible.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Pancreas: nanoparticles for optimized cancer therapy Researchers from G\u00f6ttingen and Karlsruhe have developed a new treatment approach for pancreatic cancer. The innovative method promises to be able to treat the disease in a more targeted way and with fewer side effects in the future. The therapy is now to be optimized for clinical application as …<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[],"class_list":["post-1461","post","type-post","status-publish","format-standard","hentry","category-technology"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/aqqute.com\/blog\/wp-json\/wp\/v2\/posts\/1461","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aqqute.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aqqute.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aqqute.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/aqqute.com\/blog\/wp-json\/wp\/v2\/comments?post=1461"}],"version-history":[{"count":0,"href":"https:\/\/aqqute.com\/blog\/wp-json\/wp\/v2\/posts\/1461\/revisions"}],"wp:attachment":[{"href":"https:\/\/aqqute.com\/blog\/wp-json\/wp\/v2\/media?parent=1461"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aqqute.com\/blog\/wp-json\/wp\/v2\/categories?post=1461"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aqqute.com\/blog\/wp-json\/wp\/v2\/tags?post=1461"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}